Cited by 594Estrogen and related hormone effectsAdrenal Hormones and DisordersReceptor Mechanisms and Signaling

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Genomic and nongenomic effects of glucocorticoids

Stahn, Cindy, Buttgereit, Frank·2008·Nature Clinical Practice Rheumatology

Open this paper in CoChat — free account

Abstract

The strong anti-inflammatory and immunosuppressive effects of glucocorticoids are mediated primarily by the cytosolic glucocorticoid receptors. These receptors are members of the steroid hormone receptor family, a superfamily of ligand-inducible transcription factors, and exert genomic effects that can result in increased expression of regulatory-including anti-inflammatory-proteins (transactivation), or decreased production of proinflammatory proteins (transrepression). Transactivation is thought to be responsible for numerous adverse effects of glucocorticoids; transrepression is thought to be responsible for many of the clinically desirable anti-inflammatory and immunosuppressive effects of glucocorticoids. Optimized glucocorticoids, such as selective glucocorticoid receptor agonists, are being developed to try to minimize the adverse effects many patients experience. Glucocorticoids also exert their effects via rapid, nongenomic mechanisms that can be classified as involving nonspecific interactions of glucocorticoids with cellular membranes, nongenomic effects that are mediated by cytosolic glucocorticoid receptors, or specific interactions with membrane-bound glucocorticoid receptors. Increased understanding of these mechanisms of glucocorticoid action could enable the development of novel drugs with which to treat patients with inflammatory and autoimmune disease.

Integrity signals

Registry

Crossref · 10.1038/ncprheum0898

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Primary structure and expression of a functional human glucocorticoid receptor cDNA
Hollenberg, S. M., Weinberger, C., Ong, E. S., Cerelli, G., Oro, A. E., Lebo, R. V., Thompson, E. B., Rosenfeld, M. G., & Evans, R. M. (1985) · Nature · doi:10.1038/318635a0 · Cited by 1,882
Mechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847
Oral corticosteroids and fracture risk: relationship to daily and cumulative doses
van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. C. (2000) · Lara D. Veeken · doi:10.1093/rheumatology/39.12.1383 · Cited by 699
Basic Guide to the Mechanisms of Antiestrogen Action
MacGregor, J. I., & Jordan, V. C. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01358-9 · Cited by 698
Steroid hormone receptors: an update
Beato, M. (2000) · Human Reproduction Update · doi:10.1093/humupd/6.3.225 · Cited by 615
Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase
Hafezi‐Moghadam, A., Simoncini, T., Yang, Z., Limbourg, F. P., Plumier, J.-C., Rebsamen, M. C., Hsieh, C.-M., Chui, D.-S., Thomas, K. L., Prorock, A. J., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-473 · Cited by 596
The glucocorticoid receptor inhibits NFκB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain
Nissen, R. M., & Yamamoto, K. R. (2000) · Genes & Development · doi:10.1101/gad.827900 · Cited by 559
Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology
Buttgereit, F., Da Silva, J. A. P., Boers, M., Burmester, G.-R., Cutolo, M., Jacobs, J., Kirwan, J., Köhler, L., van Riel, P., Vischer, T., et al. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.8.718 · Cited by 544
Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data
da Silva, J. A. P., Jacobs, J. W. G., Kirwan, J., Boers, M., Saag, K. G., Inês, L. B. S., de Koning, E. J. P., Buttgereit, F., Cutolo, M., Capell, H., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.038638 · Cited by 529
A corticosteroid receptor in neuronal membranes
Orchinik, M., Murray, T. F., & Moore, F. L. (1991) · Science · doi:10.1126/science.2063198 · Cited by 523
Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects
Schäcke, H., Schottelius, A., Döcke, W.-D., Strehlke, P., Jaroch, S., Schmees, N., Rehwinkel, H., Hennekes, H., & Asadullah, K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0300372101 · Cited by 466
Hormone-mediated repression: a negative glucocorticoid response element from the bovine prolactin gene.Preprint
Sakai, D. D., Helms, S. R., Carlstedt‐Duke, J., Gustafsson, J.-Α., ROTTMAN, F. M., & Yamamoto, K. R. (1988) · Genes & Development · doi:10.1101/gad.2.9.1144 · Cited by 453
The Dominant Negative Activity of the Human Glucocorticoid Receptor β Isoform
Oakley, R. H., Jewell, C. M., Yudt, M. R., Bofetiado, D. M., & Cidlowski, J. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.39.27857 · Cited by 451
The hsp90-based Chaperone System: Involvement in Signal Transduction from a Variety of Hormone and Growth Factor Receptors
Pratt, W. B. (1998) · Experimental Biology and Medicine · doi:10.3181/00379727-217-44252 · Cited by 446
Clinical Immunology: Principles and Practice
Anderson, P. C. (1996) · JAMA · doi:10.1001/jama.1996.03530390076043 · Cited by 440
Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists
Stahn, C., Löwenberg, M., Hommes, D. W., & Buttgereit, F. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.05.019 · Cited by 419
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases
Hoes, J. N., Jacobs, J. W. G., Boers, M., Boumpas, D., Buttgereit, F., Caeyers, N., Choy, E., Cutolo, M., da Silva, J. A. P., Esselens, G., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.072157 · Cited by 416
Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial
Buttgereit, F., Doering, G., Schaeffler, A., Witte, S., Sierakowski, S., Gromnica‐Ihle, E., Jeka, S., Krueger, K., Szechiński, J., & Alten, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60132-4 · Cited by 413
Rapid Actions of Steroid Receptors in Cellular Signaling Pathways
Cato, A. C. B., Nestl, A., & Mink, S. (2002) · Science s STKE · doi:10.1126/stke.2002.138.re9 · Cited by 372
Glucocorticoids in the treatment of rheumatic diseases: An update on the mechanisms of action
Buttgereit, F., Straub, R. H., Wehling, M., & Burmester, G. R. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20583 · Cited by 359
Glucocorticoids repress NF-κB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell
Bosscher, K. D., Berghe, W. V., Vermeulen, L., Plaisance, S., Boone, E., & Haegeman, G. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.8.3919 · Cited by 335
Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor‐dependent, transcription‐independent mechanism
Croxtall, J. D., Choudhury, Q., & Flower, R. J. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703272 · Cited by 332
Rapid glucocorticoid effects on immune cells
Buttgereit, F., & Scheffold, A. (2002) · Steroids · doi:10.1016/s0039-128x(01)00171-4 · Cited by 318
Complete remission of experimental arthritis by joint targeting of glucocorticoids with long‐circulating liposomes
Metselaar, J. M., Wauben, M. H. M., Wagenaar-Hilbers, J. P. A., Boerman, O. C., & Storm, G. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11140 · Cited by 303
Bioenergetics of immune functions: fundamental and therapeutic aspects
Buttgereit, F., Burmester, G. R., & Brand, M. D. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01593-0 · Cited by 284
Mouse glucocorticoid receptor phosphorylation status influences multiple functions of the receptor protein
Webster, J. C., Jewell, C. M., Bodwell, J. E., Munck, A., Sar, M., & Cidlowski, J. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.14.9287 · Cited by 261
Chaperoning of Glucocorticoid Receptors
Pratt, W. B., Morishima, Y., Murphy, M. N., & Harrell, M. (2005) · Springer eBooks · doi:10.1007/3-540-29717-0_5 · Cited by 247
Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and up‐regulated after in vitro stimulation and in patients with rheumatoid arthritis
Bartholome, B., Spies, C. M., Gaber, T., Schuchmann, S., Berki, T., Kunkel, D., Bienert, M., Radbruch, A., Burmester, G. R., Lauster, R., et al. (2004) · The FASEB Journal · doi:10.1096/fj.03-0328com · Cited by 229
Selective glucocorticoid receptor agonists (SEGRAs): Novel ligands with an improved therapeutic index
Schäcke, H., Berger, M., Rehwinkel, H., & Asadullah, K. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.05.014 · Cited by 223
Optimised glucocorticoid therapy: the sharpening of an old spear
Buttgereit, F., Burmester, G. R., & Lipworth, B. J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17989-6 · Cited by 221
The Origin and Functions of Multiple Human Glucocorticoid Receptor Isoforms
Lu, N. Z., & Cidlowski, J. A. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1321.008 · Cited by 218
The effects of non-genomic glucocorticoid mechanisms on bodily functions and the central neural system. A critical evaluation of findings
Haller, J., Mikics, É., & Makara, G. B. (2007) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2007.10.004 · Cited by 208
Non-genomic glucocorticoid effects to provide the basis for new drug developments
Song, I., & Buttgereit, F. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2005.11.012 · Cited by 208
Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands
Löwenberg, M., Stahn, C., Hommes, D. W., & Buttgereit, F. (2008) · Steroids · doi:10.1016/j.steroids.2007.12.002 · Cited by 205
Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis.
Schmidt, J., Metselaar, J. M., Wauben, M. H. M., Toyka, K. V., Storm, G., & Gold, R. (2003) · Brain · doi:10.1093/brain/awg176 · Cited by 204
Identification of phosphorylated sites in the mouse glucocorticoid receptor.
Bodwell, J. E., Ortí, E., Coull, J., Pappin, D., Smith, L. I., & Swift, F. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)89482-4 · Cited by 201
Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor
Almawi, W. Y., & Melemedjian, O. K. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.1.9 · Cited by 196
Corticosteroid-insensitive asthma: molecular mechanisms
Adcock, I. M., & Lane, S. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1780347 · Cited by 179
Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn
Löwenberg, M., Tuynman, J. B., Bilderbeek, J., Gaber, T., Buttgereit, F., van Deventer, S. J. H., Peppelenbosch, M. P., & Hommes, D. W. (2005) · Blood · doi:10.1182/blood-2004-12-4790 · Cited by 170
Structural characterization of a minimal functional transactivation domain from the human glucocorticoid receptor.
Dahlman‐Wright, K., Baumann, H., McEwan, I. J., Almlöf, T., Wright, A. P. H., Gustafsson, J.-Α., & Härd, T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1699 · Cited by 162
Glucocorticoids cause rapid dissociation of a T‐cell‐receptor‐associated protein complex containing LCK and FYN
Löwenberg, M., Verhaar, A. P., Bilderbeek, J., van Marle, J., Buttgereit, F., Peppelenbosch, M. P., van Deventer, S. J. H., & Hommes, D. W. (2006) · EMBO Reports · doi:10.1038/sj.embor.7400775 · Cited by 162
Mannheim Classification of Nongenomically Initiated (Rapid) Steroid Action(s)
Falkenstein, E., Norman, A. W., & Wehling, M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.5.6516 · Cited by 154
The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis
Buttgereit, F., Saag, K. G., Cutolo, M., da Silva, J. A. P., & Bijlsma, J. W. J. (2005) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740510017706 · Cited by 124
Plasma membrane-resident glucocorticoid receptors in rodent lymphoma and human leukemia models
Gametchua, B. (1999) · Steroids · doi:10.1016/s0039-128x(98)00097-x · Cited by 90
Mechanisms of Corticosteroid Resistance in Rheumatoid Arthritis
Chikanza, I. C. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04200.x · Cited by 88
Demonstration of nuclear translocation of the mineralocorticoid receptor (MR) using an anti-MR antibody and confocal laser scanning microscopy
Robertson, N. M., Schulman, G., Karnik, S., Alnemri, E. S., & Litwack, G. (1993) · Molecular Endocrinology · doi:10.1210/mend.7.9.8247024 · Cited by 84
Potent antiarthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis
Paul‐Clark, M. J., Mancini, L., Soldato, P. D., Flower, R. J., & Perretti, M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022641099 · Cited by 79
The plasma membrane estrogen receptor: nuclear or unclear?
Nadal, Á., Ropero, A. B., Fuentes, E., & Soria, B. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01846-0 · Cited by 71
Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein–protein interaction profile
Miner, J. N., Ardecky, B., Benbatoul, K. D., Griffiths, K., Larson, C. J., Mais, D. E., Marschke, K. B., Rosen, J., Vajda, E. G., Zhi, L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705517104 · Cited by 68
DNA Binding and Bending by the Human Papillomavirus Type 16 E2 Protein
Thain, A., Webster, K., Emery, D., Clarke, A. R., & Gaston, K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.13.8236 · Cited by 67
Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic index
Schäcke, H., Rehwinkel, H., Asadullah, K., & Cato, A. C. B. (2006) · Experimental Dermatology · doi:10.1111/j.1600-0625.2006.00453.x · Cited by 65
Glucocorticoid Receptor Nitration Leads to Enhanced Anti-Inflammatory Effects of Novel Steroid Ligands
Paul‐Clark, M. J., Roviezzo, F., Flower, R. J., Cirino, G., Soldato, P. D., Adcock, I. M., & Perretti, M. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.6.3245 · Cited by 64
Direct interaction of the tau 1 transactivation domain of the human glucocorticoid receptor with the basal transcriptional machinery.
McEwan, I. J., Wright, A. P. H., Dahlman‐Wright, K., Carlstedt‐Duke, J., & Gustafsson, J.-Α. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.1.399 · Cited by 62
Current use of glucocorticoids in patients with rheumatoid arthritis in Germany
Thiele, K., Buttgereit, F., Huscher, D., & Zink, A. (2005) · Arthritis Care & Research · doi:10.1002/art.21467 · Cited by 61
Glucocorticoid action and novel mechanisms of steroid resistance: role of glucocorticoid receptor-interacting proteins for glucocorticoid responsiveness
Wikström, A.-C. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1780331 · Cited by 60
New Glucocorticoids on the Horizon: Repress, Don't Activate!
Song, I., Gold, R., Straub, R. H., Burmester, G., & Buttgereit, F. (2005) · PubMed · Cited by 53
LGD-5552, an Antiinflammatory Glucocorticoid Receptor Ligand with Reduced Side Effects, in Vivo
LÓPEZ, F. J., Ardecky, R., Bebo, B. F., Benbatoul, K. D., de Grandpre, L. Y., Liu, S., Leibowitz, M. D., Marschke, K. B., Rosen, J., Rungta, D. K., et al. (2008) · Endocrinology · doi:10.1210/en.2007-1353 · Cited by 53
Membrane glucocorticoid receptors are down regulated by glucocorticoids in patients with systemic lupus erythematosus and use a caveolin-1-independent expression pathway
Spies, C. M., Schaumann, D., Berki, T., Mayer, K., Jakstadt, M., Huscher, D., Wunder, C., Burmester, G. R., Radbruch, A., Lauster, R., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.048272 · Cited by 50
trans-Activation and Repression Properties of the Novel Nonsteroid Glucocorticoid Receptor Ligand 2,5-Dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5-(1-methylcyclohexen-3-y1)-1H-[1]benzopyrano[3,4-f]quinoline (A276575) and Its Four Stereoisomers
Lin, C. W., Nakane, M., Stashko, M., Falls, D. H., Kuk, J. E., Miller, L. N., Huang, R., Tyree, C. M., Miner, J. N., Rosen, J., et al. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.2.297 · Cited by 49
Are Glucocorticoids DMARDs?
Bijlsma, J. W. J., Hoes, J. N., van Everdingen, A. A., Verstappen, S. M. M., & Jacobs, J. W. G. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1351.025 · Cited by 37
Generation of innovative anti-inflammatory and anti-arthritic glucocorticoid derivatives that release NO: the nitro-steroids
Perretti, M., Paul‐Clark, M. J., Mancini, L., & Flower, R. J. (2003) · Digestive and Liver Disease · doi:10.1016/s1590-8658(03)00051-3 · Cited by 25
Revisiting the Toxicity of Low‐Dose Glucocorticoids
da Silva, J. A. P., Jacobs, J. W. G., & Bijlsma, J. W. J. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1351.026 · Cited by 25
Membrane glucocorticoid receptor expression on peripheral blood mononuclear cells in patients with ankylosing spondylitis.
Tryc, A. B., Spies, C. M., Schneider, U., Kunkel, D., Berki, T., Sieper, J., Burmester, G. R., Radbruch, A., Scheffold, A., & Buttgereit, F. (2006) · PubMed · Cited by 20
Zap70 Signaling Pathway Mediates Glucocorticoid Receptor-Dependent Transcriptional Activation: Role in the Regulation of Annexin 1 Expression in T Cells
Ishaq, M., DeGray, G., Mou, K. T. Y., Aguilera, A., Yang, J., Lempicki, R. A., Hazen, A., & Natarajan, V. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.3851 · Cited by 15
Glucocorticoids
Buttgereit, F., & Burmester, G. (2008) · Springer eBooks · doi:10.1007/978-0-387-68566-3_84 · Cited by 2

Flagged first, then by citations

Research works printed but not linked: 1

Bijlsma JW et al. (2007) Systemic and intra-articular glucocorticoids in rheumatoid arthritis. In Rheumatoid arthritis, edn 2, 337–353 (Eds Firestein G. et al.) New York: Oxford University Press

Sorted by citations

Neuroinflammation and depression: A review
Troubat, R., Barone, P., Leman, S., Desmidt, T., Cressant, A., Atanasova, B., Brizard, B., El Hage, W., Surget, A., Belzung, C., et al. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.14720 · Cited by 1,107
“Once released, glucocorticoids can function in virtually all parts of the body and regulate a broad range of physiological processes through the genomic and non-genomic effects of glucocorticoid receptors (GRs) (Stahn & Buttgereit, 2008).”
Background
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Fanouriakis, A., Kostopoulou, M., Andersen, J., Aringer, M., Arnaud, L., Bae, S., Boletis, J., Bruce, I. N., Cervera, R., Doria, A., et al. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2023-224762 · Cited by 1,243
The HPA â€“ Immune Axis and the Immunomodulatory Actions of Glucocorticoids in the Brain
Bellavance, M.-A., & Rivest, S. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00136 · Cited by 419
“, GPCRs, ion channels, TCR), and cytoplasmic proteins (MAPK and phospholipases) that indirectly impact on transcriptional activity (76, 79, 101).”
Background
Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity
Lee, M., Pramyothin, P., Karastergiou, K., & Fried, S. K. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.05.029 · Cited by 399
“In addition, cytoplasmic or membrane bound GR causes rapid, nongenomic signaling [103], adding to the complexity of GC–GR mediated actions.”
Background
Glucocorticoid sensitivity in health and disease
Quax, R. A., Manenschijn, L., Koper, J. W., Hazes, J. M., Lamberts, S. W. J., van Rossum, E. F. C., & Feelders, R. A. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.183 · Cited by 310

See all 594

Authors: Stahn, C., & Buttgereit, F.
Affiliations: Charité – Universitätsmedizin Berlin (DE)
Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
Corresponding author: Buttgereit, Frank
ORCID: Buttgereit, Frank
Venue: Nature Clinical Practice Rheumatology
Publisher: Springer Science and Business Media LLC
Published: 2008-09-02
Volume: 4
Issue: 10
Pages: 525-533
ISSN: 1745-8382 (ISSN-L)
1745-8390
DOI: 10.1038/ncprheum0898
OpenAlex: W1968436319
Cited by: 594
References: 65
Citations by year: 2026: 19 · 2025: 26 · 2024: 29 · 2023: 40 · 2022: 49 · 2021: 33 · 2020: 46 · 2019: 40 · 2018: 26 · 2017: 35 · 2016: 27 · 2015: 37 · 2014: 41 · 2013: 31 · 2012: 29
FWCI: 2.66
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Clinical Practice Rheumatology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
Keywords: glucocorticoids, glucocorticoid receptor, genomic mechanisms, transcriptional activation, transrepression, steroid hormone receptors, selective glucocorticoid receptor agonists, adverse effects, anti-inflammatory activity, immunosuppression, rheumatic diseases
MeSH terms: Anti-Inflammatory Agents, Cell Membrane, Dose-Response Relationship, Drug, Glucocorticoids, Humans, Immunosuppressive Agents, Ligands, Receptors, Glucocorticoid, Rheumatology, Transcriptional Activation, Genomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Genomic and nongenomic effects of glucocorticoids

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks